Honeywell Aerospace Inc. Common Stock vs 10X Genomics Inc — how do they compare? Honeywell Aerospace Inc. Common Stock trades at $155.9 (market cap $50.14B), while 10X Genomics Inc trades at $71.84 (market cap $9.35B). The key difference: Honeywell Aerospace Inc. Common Stock is far larger — about 5.4× 10X Genomics Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Honeywell Aerospace Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Honeywell Aerospace Inc. Common Stock for 0 Days and 10X Genomics Inc for 91 Days on average.
| HONA | TXG | |
|---|---|---|
Market Cap | $50.14B | $9.35B |
Volume | 1,433,364 | 4,039,449 |
Sector | Industrials | Health |
52-Week High | $269.95 | $97.74 |
52-Week Low | $151.58 | $11.83 |
Typical Hold Time | 0 Days | 91 Days |
Enterprise Value | $64.96B | $8.88B |
Signals from Pluang's Aura AI — not financial advice
HONA trades at $158.18, up 0.58% today, with neutral technical indicators showing support at $156 and resistance at $160. The company reported Q2 2026 EPS of $1.87, missing expectations of $2.07, while revenue grew to $17.40B in 2025. Analyst consensus remains mixed with a $211.25 price target, but multiple class action lawsuits filed in October 2026 create significant legal overhang.
HONA faces near-term headwinds from earnings miss and legal challenges, though strong cash flow generation and analyst price targets suggest long-term potential. Investors should weigh the 42.9% buy rating against litigation risks and declining profit margins projected for 2026.
TXG trades at $73.10, down 2.78% on the day, with a bearish technical signal and neutral oscillators. The company reported revenue of $642.82M in 2025 but a net loss of $43.54M, though recent quarters show earnings beats. Analyst consensus is mixed with a $83.30 price target. Positive news includes Atera shipments and a patent victory, but profitability remains a challenge.
The outlook hinges on Atera's commercial success driving future revenue growth and margin improvement. Risks include persistent losses, competitive pressures, and execution delays. Upside potential exists if new platforms gain traction, but investors should weigh high valuation multiples against ongoing unprofitability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Honeywell Aerospace Inc. is an aerospace and defense technology company, spun off from Honeywell in June 2026, that designs and supplies avionics, propulsion components (including auxiliary power units and engines), and connectivity systems for commercial, defense, and space aircraft.
Read more on HONA →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →